CellProthera

CellProthera is a clinical-stage biotech focused on autologous cell therapy for cardiac regeneration. Its core technology is a bioproduction platform that expands a patient's CD34+ stem cells, which are then re-injected to promote healing after a severe heart attack. The company has reported Phase I/IIb results and is advancing its lead program, having recently acquired a transendocardial catheter delivery system to enhance its therapeutic delivery. CellProthera represents a personalized medicine approach to addressing the significant unmet need in heart failure.

Proprietary bioproduction platform for the expansion of autologous CD34+ stem cells (ProtheraCytes®) for cardiac regeneration, combined with a transendocardial catheter for precise intramyocardial delivery.

CellProthera competes in the cardiac cell therapy space, which includes other companies developing autologous and allogeneic stem cell therapies (e.g., using mesenchymal stem cells, cardiosphere-derived cells). It also competes indirectly with pharmaceutical heart failure drugs, device therapies, and other regenerative approaches. Its differentiation lies in its specific CD34+ cell focus and integrated delivery system.